When the abstract reports a well-tolerated treatment, the data should support it

Affiliations

Comment

Bruno M Strebel. J Clin Oncol. 2014.

. 2014 Feb 10;32(5):478-9.

doi: 10.1200/JCO.2013.52.5451. Epub 2013 Dec 30.

No abstract available

Comment in

Reply to B.M. Strebel.
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Kim JH, Ahn MJ, Aerts JG, Vikström A, Groen HJ. Barlesi F, et al. J Clin Oncol. 2014 Feb 10;32(5):479-80. doi: 10.1200/JCO.2013.53.7175. Epub 2013 Dec 30. J Clin Oncol. 2014. PMID: 24378413 No abstract available.

Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Barlesi F, et al. J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8. J Clin Oncol. 2013. PMID: 23835708 Clinical Trial.